NCT03458728 2023-12-04Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric PatientsBayerPhase 1/2 Terminated31 enrolled 17 charts
NCT03803761 2023-09-25A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerNational Cancer Institute (NCI)Phase 1/2 Withdrawn